Debt-to-equity of Summit Therapeutics Inc. from 31 Mar 2021 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Summit Therapeutics Inc. quarterly Debt-to-equity in % history and change rate from 31 Mar 2021 to 31 Dec 2025.
  • Summit Therapeutics Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 18%, a 50% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Summit Therapeutics Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 18% -18% -50% 31 Dec 2025
Q3 2025 19% -44% -70% 30 Sep 2025
Q2 2025 15% -111% -88% 30 Jun 2025
Q1 2025 22% -123% -85% 31 Mar 2025
Q4 2024 37% -76% -67% 31 Dec 2024
Q3 2024 62% -125% -67% 30 Sep 2024
Q2 2024 126% -30% -19% 30 Jun 2024
Q1 2024 145% -18% -11% 31 Mar 2024
Q4 2023 112% -62% -36% 31 Dec 2023
Q3 2023 187% +142% +318% 30 Sep 2023
Q2 2023 156% +105% +207% 30 Jun 2023
Q1 2023 163% +127% +348% 31 Mar 2023
Q4 2022 175% +132% +306% 31 Dec 2022
Q3 2022 45% +3.2% +7.7% 30 Sep 2022
Q2 2022 51% +2.5% +5.3% 30 Jun 2022
Q1 2022 36% -22% -38% 31 Mar 2022
Q4 2021 43% 31 Dec 2021
Q3 2021 42% 30 Sep 2021
Q2 2021 48% 30 Jun 2021
Q1 2021 59% 31 Mar 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.